Approved CAR-T products in the United States as of March 2023
| Generic name . | Trade name . | Target . | Indication . |
|---|---|---|---|
| Tisagenlecleucel | Kymriah | CD19 | B-cell acute lymphoblastic leukemia among those aged <26 with refractory or multiply relapsed disease. Adult patients with relapsed or refractory large B-cell or follicular lymphoma after ≥2 lines of therapy. |
| Axicabtagene ciloleucel | Yescarta | CD19 | Adult patients with relapsed or refractory large B-cell or follicular lymphoma after ≥2 lines of therapy. Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. |
| Lisocabtagene maraleucel | Breyanzi | CD19 | Adult patients with relapsed or refractory large B-cell lymphoma after ≥2 lines of therapy or that is refractory to first-line therapy or that relapses within 12 mo of first-line therapy. |
| Brexucabtagene autoleucel | Tecartus | CD19 | Adult patients with relapsed or refractory mantle-cell lymphoma. Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. |
| Idecabtagene vicleucel | Abecma | BCMA | Relapsed or refractory multiple myeloma after ≥4 prior lines of therapy. |
| Ciltacabtagene autoleucel | Carvykti | BCMA | Relapsed or refractory multiple myeloma after ≥4 prior lines of therapy. |
| Generic name . | Trade name . | Target . | Indication . |
|---|---|---|---|
| Tisagenlecleucel | Kymriah | CD19 | B-cell acute lymphoblastic leukemia among those aged <26 with refractory or multiply relapsed disease. Adult patients with relapsed or refractory large B-cell or follicular lymphoma after ≥2 lines of therapy. |
| Axicabtagene ciloleucel | Yescarta | CD19 | Adult patients with relapsed or refractory large B-cell or follicular lymphoma after ≥2 lines of therapy. Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. |
| Lisocabtagene maraleucel | Breyanzi | CD19 | Adult patients with relapsed or refractory large B-cell lymphoma after ≥2 lines of therapy or that is refractory to first-line therapy or that relapses within 12 mo of first-line therapy. |
| Brexucabtagene autoleucel | Tecartus | CD19 | Adult patients with relapsed or refractory mantle-cell lymphoma. Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. |
| Idecabtagene vicleucel | Abecma | BCMA | Relapsed or refractory multiple myeloma after ≥4 prior lines of therapy. |
| Ciltacabtagene autoleucel | Carvykti | BCMA | Relapsed or refractory multiple myeloma after ≥4 prior lines of therapy. |
BCMA, B-cell maturation antigen.